Key result
C-reactive protein levels at diagnosis did not predict survival or death/heart transplant in patients with myocarditis (p=0.23).
Why the study?
The role of inflammation markers in myocarditis is unclear.
Does abnormal CRP at diagnosis predict death or heart transplant in patients with myocarditis?
Cohort (n=409)
Does abnormal CRP at diagnosis predict death or heart transplant in patients with myocarditis?
p-value: p=0.23
Raised CRP at diagnosis in myocarditis is associated with less severe clinical features but does not predict long-term survival or need for heart transplant.
CRP does not predict survival or transplant need in myocarditis; leaves open its added value beyond LVEF and ANA in prospective cohorts.
Aims: The role of inflammation markers in myocarditis is unclear. We assessed the diagnostic and prognostic correlates of C-reactive protein (CRP) at diagnosis in patients with myocarditis. Methods and results: We retrospectively enrolled patients with clinically suspected (CS) or biopsy-proven (BP) myocarditis, with available CRP at diagnosis. Clinical, laboratory and imaging data were collected at diagnosis and at follow-up visits. To evaluate predictors of death/heart transplant (Htx), a machine-learning approach based on random forest for survival data was employed. We included 409 patients (74% males, aged 37 ± 15, median follow-up 2.9 years). Abnormal CRP was reported in 288 patients, mainly with CS myocarditis (p < 0.001), recent viral infection, shorter symptoms duration (p = 0.001), chest pain (p < 0.001), better functional class at diagnosis (p = 0.018) and higher troponin I values (p < 0.001). Death/Htx was reported in 13 patients, of whom 10 had BP myocarditis (overall 10-year survival 94%). Survival rates did not differ according to CRP levels (p = 0.23). The strongest survival predictor was LVEF, followed by anti-nuclear auto-antibodies (ANA) and BP status. Conclusions: Raised CRP at diagnosis identifies patients with CS myocarditis and less severe clinical features, but does not contribute to predicting survival. Main death/Htx predictors are reduced LVEF, BP diagnosis and positive ANA.
No takes yet. Share an insight, caveat, or question.
Baritussio et al. (2022) conducted a cohort in Myocarditis (n=409). C-reactive protein (CRP) at diagnosis vs. Normal CRP levels was evaluated on Death/heart transplant (Htx) (p=0.23). C-reactive protein levels at diagnosis did not predict survival or death/heart transplant in patients with myocarditis (p=0.23).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: